Research ArticleClinical Investigations
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A. O’Donoghue, Shutian Ruan, Serge K. Lyashchenko, Jorge A. Carrasquillo, Glenn Heller, Danny F. Martinez, Sarah M. Cheal, Jason S. Lewis, Martin Fleisher, Jennifer S. Keppler, Robert E. Reiter, Anna M. Wu, Wolfgang A. Weber, Howard I. Scher, Steven M. Larson and Michael J. Morris
Journal of Nuclear Medicine December 2016, 57 (12) 1858-1864; DOI: https://doi.org/10.2967/jnumed.116.176206
Neeta Pandit-Taskar
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
Joseph A. O’Donoghue
3Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York
Shutian Ruan
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Serge K. Lyashchenko
4Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York
Jorge A. Carrasquillo
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
Glenn Heller
5Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
Danny F. Martinez
6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Sarah M. Cheal
7Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
Jason S. Lewis
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
4Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York
7Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
Martin Fleisher
8Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
Jennifer S. Keppler
9ImaginAb, Inc., Inglewood, California; and
Robert E. Reiter
9ImaginAb, Inc., Inglewood, California; and
Anna M. Wu
9ImaginAb, Inc., Inglewood, California; and
Wolfgang A. Weber
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
Howard I. Scher
6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
10Department of Medicine, Weill Cornell Medical College, New York, New York
Steven M. Larson
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
7Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
Michael J. Morris
6Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
10Department of Medicine, Weill Cornell Medical College, New York, New York

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 12
December 1, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A. O’Donoghue, Shutian Ruan, Serge K. Lyashchenko, Jorge A. Carrasquillo, Glenn Heller, Danny F. Martinez, Sarah M. Cheal, Jason S. Lewis, Martin Fleisher, Jennifer S. Keppler, Robert E. Reiter, Anna M. Wu, Wolfgang A. Weber, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal of Nuclear Medicine Dec 2016, 57 (12) 1858-1864; DOI: 10.2967/jnumed.116.176206
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A. O’Donoghue, Shutian Ruan, Serge K. Lyashchenko, Jorge A. Carrasquillo, Glenn Heller, Danny F. Martinez, Sarah M. Cheal, Jason S. Lewis, Martin Fleisher, Jennifer S. Keppler, Robert E. Reiter, Anna M. Wu, Wolfgang A. Weber, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal of Nuclear Medicine Dec 2016, 57 (12) 1858-1864; DOI: 10.2967/jnumed.116.176206
Jump to section
Related Articles
Cited By...
- 11C Dosimetry Scans Should Be Abandoned
- First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
- Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies
- Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
- Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer
- Immune Modulation Therapy and Imaging: Workshop Report
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding